Fresenius SE & Co. KGaA

Fresenius reported Q2 organic revenue growth of 6%, constant-currency EBIT growth of 10%, and core EPS growth of 14% at constant currency. Group EBIT margin improved 60 basis points year over year to 12.3%. Kabi organic revenue grew 7% and its EBIT margin was 17.9%, while Helios organic revenue grew 5% and its EBIT margin was 10.6%; Helios Germany EBIT margin was 8.3% and Helios Spain EBIT margin was 14%. Operating cash flow in Q2 was EUR 344 million; last-12-month operating cash flow from continuing operations was EUR 2.8 billion and free cash flow was EUR 1.6 billion. Leverage remained 2.6x net debt-to-EBITDA. Management raised full-year core EPS growth guidance at constant currency to 10% to 15% from 5% to 10%. Kabi full-year EBIT margin is now expected at the upper end of 16.5% to 17%, and interest expense is now expected to be slightly below the prior year.

Michael Sen framed the quarter as evidence that Fresenius is becoming a higher-quality, more resilient company, with growth vectors contributing more meaningfully to earnings and cash generation. He emphasized that biopharma, MedTech and care provision are now scalable platforms rather than emerging opportunities, and said the company is using its stronger balance sheet and lower leverage to preserve strategic flexibility. His tone was confident and constructive, but he repeatedly stressed disciplined capital allocation rather than chasing margin expansion for its own sake.

Sara Hennicken focused on the financial conversion of growth into earnings and cash, highlighting 6% organic revenue growth, 10% EBIT growth, 60 bps of margin expansion to 12.3%, and 14% core EPS growth at constant currency. She cited a 24.8% tax rate, Q2 operating cash flow of EUR 344 million, LTM operating cash flow of EUR 2.8 billion, LTM free cash flow of EUR 1.6 billion, and leverage of 2.6x net debt-to-EBITDA despite the dividend. She also raised the full-year core EPS outlook to 10% to 15%, guided Kabi margin to the upper end of 16.5% to 17%, and said interest expense should be slightly below the prior year.

Analysts pressed on the wide second-half EPS range, with management saying Q4 will face tough comps and that it is more important to focus on operational momentum than quarter-to-quarter phasing. Questions also centered on whether biopharma is becoming more diversified, and management said the platform now has 11 products on 8 molecules, with more launches coming in Q3 and Q4, but that it is still not a 'margin maxing' story and may require further investment. On Melrose Park, management said the FDA status reflects work that needs to be done, but the plant remains operational, there should be no material impact in 2026 or 2027, and the broader U.S. manufacturing network provides flexibility.